KLK13

Summary

KLK13 (kallikrein related peptidase 13, HGNC:6361) is a protein-coding gene on chromosome 19q13.41, encoding Kallikrein-13 (Q9UKR3).

Kallikreins are a subgroup of serine proteases having diverse physiological functions. Growing evidence suggests that many kallikreins are implicated in carcinogenesis and some have potential as novel cancer and other disease biomarkers. This gene is one of the fifteen kallikrein subfamily members located in a cluster on chromosome 19. Expression of this gene is regulated by steroid hormones and may be useful as a marker for breast cancer.

Source: NCBI Gene 26085 — RefSeq curated summary.

At a glance

• GWAS associations: 2
• Clinical variants (ClinVar): 60 total
• Druggable target: yes
• MANE Select transcript: NM_015596

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:6361
Approved symbol	KLK13
Name	kallikrein related peptidase 13
Location	19q13.41
Locus type	gene with protein product
Status	Approved
Aliases	KLK-L4
Ensembl gene	ENSG00000167759
Ensembl biotype	protein_coding
OMIM	605505
Entrez	26085

Gene structure

Transcript identifiers

Ensembl transcripts: 9 — 5 nonsense_mediated_decay, 4 protein_coding

ENST00000156476, ENST00000335422, ENST00000376799, ENST00000441527, ENST00000595547, ENST00000595793, ENST00000596955, ENST00000601975, ENST00000602090

RefSeq mRNA: 3 — MANE Select: NM_015596 NM_001348177, NM_001348178, NM_015596

CCDS: CCDS12822, CCDS86794, CCDS86795

Canonical transcript exons

ENST00000595793 — 5 exons

Exon	Start	End
ENSE00002282156	51059825	51060093
ENSE00003128780	51055626	51056775
ENSE00003485015	51060433	51060619
ENSE00003573735	51058538	51058674
ENSE00003844395	51065016	51065092

Expression profiles

Bgee: expression breadth ubiquitous, 169 present calls, max score 99.65.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.0956 / max 12.2105, expressed in 35 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
182370	0.0727	24
182369	0.0229	9

Top tissues by expression

290 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
lower esophagus mucosa	UBERON:0035834	99.65	gold quality
esophagus mucosa	UBERON:0002469	98.75	gold quality
pharyngeal mucosa	UBERON:0000355	97.60	gold quality
gingiva	UBERON:0001828	95.64	gold quality
epithelium of esophagus	UBERON:0001976	95.40	gold quality
esophagus squamous epithelium	UBERON:0006920	95.39	gold quality
oral cavity	UBERON:0000167	94.82	gold quality
gingival epithelium	UBERON:0001949	94.69	gold quality
body of tongue	UBERON:0011876	94.23	gold quality
mammalian vulva	UBERON:0000997	93.22	gold quality
tongue squamous epithelium	UBERON:0006919	92.29	gold quality
squamous epithelium	UBERON:0006914	91.66	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	89.54	gold quality
penis	UBERON:0000989	89.38	gold quality
cervix epithelium	UBERON:0004801	87.51	gold quality
tongue	UBERON:0001723	87.09	gold quality
vagina	UBERON:0000996	84.97	gold quality
skin of leg	UBERON:0001511	84.55	gold quality
buccal mucosa cell	CL:0002336	83.92	gold quality
skin of abdomen	UBERON:0001416	82.91	gold quality
zone of skin	UBERON:0000014	80.87	gold quality
tonsil	UBERON:0002372	79.75	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	79.46	gold quality
esophagus	UBERON:0001043	79.31	gold quality
amniotic fluid	UBERON:0000173	78.92	gold quality
mouth mucosa	UBERON:0003729	78.10	gold quality
superior surface of tongue	UBERON:0007371	77.95	gold quality
minor salivary gland	UBERON:0001830	75.38	gold quality
left testis	UBERON:0004533	73.52	gold quality
right testis	UBERON:0004534	73.01	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	15.40

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

37 targeting KLK13, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-12118	100.00	65.88	1270
HSA-MIR-34A-5P	99.99	71.21	1784
HSA-MIR-449A	99.99	71.05	1776
HSA-MIR-4534	99.99	66.58	1907
HSA-MIR-6891-5P	99.98	66.53	1372
HSA-MIR-3173-3P	99.98	66.49	1217
HSA-MIR-3688-3P	99.97	72.02	2834
HSA-MIR-34C-5P	99.97	70.45	1577
HSA-MIR-449B-5P	99.97	70.26	1580
HSA-MIR-3658	99.96	73.87	4379
HSA-MIR-1-3P	99.93	72.35	1914
HSA-MIR-206	99.93	72.50	1893
HSA-MIR-613	99.91	71.50	1710
HSA-MIR-4428	99.73	66.41	1733
HSA-MIR-4802-3P	99.72	70.13	1273
HSA-MIR-378G	99.71	64.90	1106
HSA-MIR-4502	99.65	66.99	1021
HSA-MIR-4437	99.52	65.29	1266
HSA-MIR-6081	99.48	66.07	1446
HSA-MIR-1324	99.46	66.57	1302
HSA-MIR-653-5P	99.46	67.35	1300
HSA-MIR-3915	99.45	68.49	1905
HSA-MIR-2392	99.43	67.50	708
HSA-MIR-9986	98.91	69.28	1024
HSA-MIR-4656	98.79	66.22	1306
HSA-MIR-5000-3P	98.79	65.63	1251
HSA-MIR-11399	98.71	65.69	869
HSA-MIR-1302	97.92	67.27	844
HSA-MIR-204-3P	97.80	66.84	1656
HSA-MIR-4646-5P	97.70	66.84	1692

Literature-anchored findings (GeneRIF, showing 25)

• KLK13 expression is an independent favorable prognostic marker for breast carcinoma (PMID:11986781)
• kallikrein 13 is expressed in the nonmalignant and malignant prostate, with cancer tissues demonstrating slightly lower expression (PMID:12970725)
• hK13 interacts and forms complexes with serum protease inhibitors, including alpha2-macroglobulin, alpha1-antichymotrypsin and alpha2-antiplasmin (PMID:14687906)
• Human kallikrein13 may play a role in tissue remodeling and/or tumor invasion and metastasis. (PMID:15381110)
• hK13 is expressed in several common salivary gland tumors (PMID:16847813)
• non-small-cell lung cancer patients with high KLK13 expression at the mRNA or protein level had lower overall survival (PMID:18627302)
• Combination of KLK2, 3, 13, and 14 and KLK1, 2, 5, 6, 7, 8, 10, 13, and 14 showed very strong discriminatory potential for semen liquefaction and viscosity, respectively. (PMID:19558318)
• KLK6 and KLK13 predict tumor recurrence in epithelial ovarian carcinoma. (PMID:19707197)
• This is the first study disclosing the possible clinical utility of KLK13 as a new tumor biomarker capable of predicting a favorable outcome for gastric cancer patients. (PMID:20678496)
• Serine protease of Kazal-type (SPINK6) expressed in normal human skin is a potent natural inhibitor of Kallikrein-related peptidases, KLK12 and KLK13. (PMID:21439340)
• these results reveal the enhancing effects of KLK13 on tumor cell invasion and migration, and that it may serve as a diagnostic/prognostic marker and a potential therapeutic target for lung cancer. (PMID:21596022)
• Results indicate that KLK13 may play a role in the defense of the upper digestive apparatus and in male reproductive organs. (PMID:21689719)
• Data indicate that five out of 9 SNPs in the KLK13 gene were associated with prostate cancer risk and/or aggressiveness. (PMID:21741862)
• High KLK13 expression is associated with drug response in gastric cancer. (PMID:22948777)
• KLK13 may play an important role in regulating cellular migration and invasiveness, making the loss of KLK13 a potential biomarker for early detection of lymph node metastasis in oral squamous cell carcinomas. (PMID:23371469)
• The aim of this study was to monitor serum levels of two microRNAs (miR-21 and miR-141) and three kallikreins (hK3/PSA, hK11, and hK13) before and 1, 5, and 30 days after radical prostatectomy. (PMID:24288670)
• Our results suggest that KLK13 mRNA expression constitutes a novel biomarker for the prediction of overall survival in nonsmall cell lung cancer and that its quantitative assessment in tumor tissues can aid in treatment decision making. (PMID:25677900)
• This first clinical study of KLK13 in bladder cancer reveals its deregulated expression in bladder tumors and highlights KLK13 as a promising marker for improving TaT1 patients’ prognosis following treatment. (PMID:27858162)
• Decreased KLK13 mRNA levels correlate with poor survival in esophageal squamous cell carcinoma patients. (PMID:29221724)
• There was no significant association of KLK13 and KLK14 mRNA expression with the clinical factors ascitic fluid volume or residual tumor mass. In univariate Cox regression analysis, elevated KLK13 mRNA levels were significantly linked with shorter progression-free (PFS; hazard ratio [HR] = 1.97, P = 0.020) and overall survival (OS; HR = 1.81, P = 0.041). (PMID:29546479)
• Relatively high levels of KLK13 expression in ESCC were associated with cell proliferation and correlated with tumor progression, advanced cancer stage, and poor prognosis (PMID:29582368)
• serine proteases transmembrane protein serine 11D and kallikrein-related peptidase 13 were shown as active proteases in Cervical-vaginal fluid. (PMID:30647911)
• LncRNA WT-AS inhibits metastatic ability of non-small cell lung cancer by regulating KLK13. (PMID:33015785)
• Kallikrein 13 serves as a priming protease during infection by the human coronavirus HKU1. (PMID:33234691)
• Analysis of urinary kallikrein-related peptidase 13 for monitoring bladder cancer. (PMID:34704886)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Klk13	ENSMUSG00000054046
rattus_norvegicus	Klk13	ENSRNOG00000022353

Paralogs (6): CMA1 (ENSG00000092009), CTSG (ENSG00000100448), GZMH (ENSG00000100450), GZMB (ENSG00000100453), KLK6 (ENSG00000167755), AZU1 (ENSG00000172232)

Protein

Protein identifiers

Kallikrein-13 — Q9UKR3 (reviewed: Q9UKR3)

Alternative names: Kallikrein-like protein 4

All UniProt accessions (7): A0A1R3UCE9, Q9UKR3, M0R218, Q5BQ95, Q5BQ97, Q5BQ99, Q86VI7

UniProt curated annotations — full annotation on UniProt →

Subcellular location. Secreted.

Tissue specificity. Expressed in prostate, breast, testis and salivary gland.

Similarity. Belongs to the peptidase S1 family. Kallikrein subfamily.

Isoforms (2)

UniProt ID	Names	Canonical?
Q9UKR3-1	1	yes
Q9UKR3-2	2

RefSeq proteins (3): NP_001335106, NP_001335107, NP_056411* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001254	Trypsin_dom	Domain
IPR001314	Peptidase_S1A	Family
IPR009003	Peptidase_S1_PA	Homologous_superfamily
IPR018114	TRYPSIN_HIS	Active_site
IPR033116	TRYPSIN_SER	Active_site
IPR043504

Pfam: PF00089

Enzyme classification (BRENDA):

• EC 3.4.21.119 — kallikrein 13 (BRENDA: 2 organisms, 40 substrates, 16 inhibitors, 8 Km, 8 kcat entries)

Substrate kinetics (BRENDA)

6 substrates with measured Km, best-characterized 6. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
ABZ-KLKSSKQ-EDDNP	0.0053–0.031	2
ABZ-KLRSSKQ-EDDNP	0.0012–0.0022	2
ABZ-VAL-ARG-PHE-ARG-5-AMINO-2-NITROBENZOIC ACID	0.018	1
ABZ-VRFRSTG-TYR(3-NO2)-NH2	0.02	1
ABZ-VRFRSTQ-TYR(3-NO2)-NH2	0.01	1
ABZ-VRFRSTS-TYR(3-NO2)-NH2	0.015	1

UniProt features (15 total): disulfide bond 5, active site 3, glycosylation site 2, signal peptide 1, chain 1, splice variant 1, sequence variant 1, domain 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9UKR3-F1	86.73	0.72

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (3): 76 (charge relay system); 124 (charge relay system); 218 (charge relay system)

Disulfide bonds (5): 157–224, 189–203, 214–239, 42–178, 61–77

Glycosylation sites (2): 30, 225

Function

Pathways and Gene Ontology

Reactome pathways

5 pathways

ID	Pathway
R-HSA-381426	Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)
R-HSA-6809371	Formation of the cornified envelope
R-HSA-1266738	Developmental Biology
R-HSA-392499	Metabolism of proteins
R-HSA-6805567	Keratinization

MSigDB gene sets: 64 (showing top): RNGTGGGC_UNKNOWN, GOCC_SECRETORY_GRANULE, LFA1_Q6, HNF1_Q6, GGGTGGRR_PAX4_03, CAGCTG_AP4_Q5, GOBP_PROTEIN_MATURATION, MODULE_285, BLALOCK_ALZHEIMERS_DISEASE_UP, ARGGGTTAA_UNKNOWN, PU1_Q6, HNF1_C, TGGNNNNNNKCCAR_UNKNOWN, VDR_Q3, GOCC_SECRETORY_VESICLE

GO Biological Process (3): proteolysis (GO:0006508), protein processing (GO:0016485), protein maturation (GO:0051604)

GO Molecular Function (6): serine-type endopeptidase activity (GO:0004252), hydrolase activity (GO:0016787), endopeptidase activity (GO:0004175), protein binding (GO:0005515), peptidase activity (GO:0008233), serine-type peptidase activity (GO:0008236)

GO Cellular Component (4): extracellular region (GO:0005576), obsolete extracellular space (GO:0005615), cytoplasm (GO:0005737), secretory granule (GO:0030141)

Reactome top-level categories

Rollup of top-3 pathways:

Category	Pathways
Metabolism of proteins	1
Keratinization	1
Developmental Biology	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
protein metabolic process	2
peptidase activity	2
cellular anatomical structure	2
proteolysis	1
protein maturation	1
gene expression	1
endopeptidase activity	1
serine-type peptidase activity	1
catalytic activity	1
binding	1
hydrolase activity	1
catalytic activity, acting on a protein	1
serine hydrolase activity	1
intracellular anatomical structure	1
endomembrane system	1
secretory vesicle	1

Protein interactions and networks

STRING

795 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
KLK13	SIGLEC9	Q9Y336	762
KLK13	SPINK6	Q6UWN8	586
KLK13	SPINK5	Q9NQ38	517
KLK13	SPINK7	P58062	453
KLK13	SEMG2	Q02383	424
KLK13	KLK14	Q9P0G3	424
KLK13	GPC1	P35052	415
KLK13	SERPINB13	Q9UIV8	380
KLK13	CAMP	P49913	357
KLK13	CNFN	Q9BYD5	350
KLK13	TGM3	Q08188	347
KLK13	CDSN	Q15517	346
KLK13	LCE6A	A0A183	334
KLK13	KRT4	P19013	324
KLK13	CRNN	Q9UBG3	322

IntAct

7 interactions, top by confidence:

A	B	Type	Score
KLK13	SERPINE2	psi-mi:“MI:0915”(physical association)	0.400
ATG16L1		psi-mi:“MI:0914”(association)	0.350
KLK13	SERPINE2	psi-mi:“MI:0914”(association)	0.350
CCR1	UBA6	psi-mi:“MI:0914”(association)	0.350
FNDC5	A2ML1	psi-mi:“MI:0914”(association)	0.350
KLK13	LDLRAP1	psi-mi:“MI:0914”(association)	0.350

BioGRID (16): SERPINB6 (Affinity Capture-MS), SERPINE2 (Affinity Capture-MS), SERPINA3 (Reconstituted Complex), SERPINF2 (Reconstituted Complex), SERPINE2 (Affinity Capture-MS), A2M (Reconstituted Complex), SERPINB6 (Affinity Capture-MS), SERPINE2 (Affinity Capture-MS), LDLRAP1 (Affinity Capture-MS), KLK13 (Affinity Capture-MS), C12orf5 (Affinity Capture-MS), KLK13 (Affinity Capture-MS), KLK9 (Negative Genetic), KLK13 (Affinity Capture-MS), KLK13 (Affinity Capture-MS)

ESM2 similar proteins: A1L453, A2VE36, A6NIE9, A8MTI9, E5RG02, O43240, O70169, P09582, P50343, P83748, Q14B25, Q14BX2, Q16651, Q3UKY7, Q3V0Q7, Q402U7, Q571E5, Q5FBW1, Q5K2P8, Q5K2P9, Q5M8S2, Q6AXZ6, Q6BEA2, Q6IE62, Q6IE63, Q6UWB4, Q76B45, Q76HL1, Q7RTY3, Q7RTY5, Q7RTY9, Q7Z5A4, Q8BJR6, Q8BLH5, Q8K4I7, Q8VIF2, Q920S2, Q99MS4, Q9BQR3, Q9D9M0

Diamond homologs: A0A1S4GMJ4, A6NIE9, A8JUP7, G3V801, O08762, O42207, O60235, P00741, P00745, P00762, P00765, P03951, P05049, P07477, P07478, P0CW18, P15120, P16292, P16295, P19799, P29786, P29787, P35030, P35039, P69525, P79953, Q14B25, Q14BX2, Q14C59, Q1JRP2, Q27081, Q28278, Q28315, Q28412, Q29463, Q2KJ63, Q2VG86, Q5G265, Q5U405, Q6BEA2

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

60 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	56
Likely benign	2
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

751 predictions. Top by Δscore:

Variant	Effect	Δscore
19:51058532:CCTCA:C	donor_loss	1.0000
19:51058533:CTCAC:C	donor_loss	1.0000
19:51058534:TCA:T	donor_loss	1.0000
19:51058535:CA:C	donor_loss	1.0000
19:51058536:A:T	donor_loss	1.0000
19:51058671:TTCA:T	acceptor_gain	1.0000
19:51058675:C:CC	acceptor_gain	1.0000
19:51059918:AG:A	donor_gain	1.0000
19:51060090:CCCC:C	acceptor_gain	1.0000
19:51060091:CCC:C	acceptor_gain	1.0000
19:51060091:CCCC:C	acceptor_gain	1.0000
19:51060092:CC:C	acceptor_gain	1.0000
19:51060092:CCC:C	acceptor_gain	1.0000
19:51060093:CC:C	acceptor_gain	1.0000
19:51060573:A:AC	donor_gain	1.0000
19:51060574:C:CC	donor_gain	1.0000
19:51056774:CC:C	acceptor_gain	0.9900
19:51056775:CC:C	acceptor_gain	0.9900
19:51056776:C:T	acceptor_gain	0.9900
19:51056781:T:TC	acceptor_gain	0.9900
19:51058551:TTGCC:T	donor_gain	0.9900
19:51058598:T:A	donor_gain	0.9900
19:51058670:ATTCA:A	acceptor_gain	0.9900
19:51058672:TCA:T	acceptor_gain	0.9900
19:51058673:CA:C	acceptor_gain	0.9900
19:51058673:CAC:C	acceptor_gain	0.9900
19:51059823:AC:A	donor_gain	0.9900
19:51059824:CC:C	donor_gain	0.9900
19:51060089:GCCCC:G	acceptor_gain	0.9900
19:51060090:CCCCC:C	acceptor_gain	0.9900

AlphaMissense

1762 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
19:51059847:C:A	W162C	0.999
19:51059847:C:G	W162C	0.999
19:51059962:T:A	D124V	0.999
19:51058575:C:G	C203S	0.998
19:51058576:A:T	C203S	0.998
19:51056650:C:A	W257C	0.997
19:51056650:C:G	W257C	0.997
19:51058617:C:G	C189S	0.997
19:51058618:A:T	C189S	0.997
19:51059849:A:G	W162R	0.997
19:51059849:A:T	W162R	0.997
19:51059962:T:G	D124A	0.997
19:51059963:C:G	D124H	0.997
19:51056765:C:A	G219V	0.996
19:51056771:T:A	D217V	0.996
19:51056771:T:G	D217A	0.996
19:51058542:C:G	C214S	0.996
19:51058543:A:T	C214S	0.996
19:51058576:A:G	C203R	0.996
19:51059963:C:A	D124Y	0.996
19:51060441:A:C	C77W	0.996
19:51056756:A:G	L222P	0.995
19:51056765:C:T	G219E	0.995
19:51056766:C:A	G219W	0.995
19:51056769:A:G	S218P	0.995
19:51056772:C:G	D217H	0.995
19:51058542:C:T	C214Y	0.995
19:51058575:C:T	C203Y	0.995
19:51058618:A:G	C189R	0.995
19:51059846:C:A	G163C	0.995

dbSNP variants (sampled 300 via entrez): RS1000065595 (19:51055233 G>C,T), RS1000475319 (19:51067358 G>C), RS1000550319 (19:51058029 T>C), RS1000577423 (19:51061924 C>T), RS1000784158 (19:51067023 T>A), RS1001474517 (19:51056721 A>G), RS1001560544 (19:51059512 A>T), RS1001634356 (19:51062287 T>C), RS1001908119 (19:51056043 T>C), RS1002158448 (19:51059245 T>C), RS1002506229 (19:51057384 C>A,T), RS1002668352 (19:51063436 T>C,G), RS1002929708 (19:51066049 T>C), RS1002973450 (19:51060762 G>C), RS1002993349 (19:51057109 C>T)

Disease associations

OMIM: gene MIM:605505 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST006585_2077	Blood protein levels	4.000000e-54
GCST006585_958	Blood protein levels	3.000000e-27

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL4863 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

1 potent at pChembl≥5 of 1 total, top 1 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
6.09	Ki	820	nM	CHEMBL4070056

PubChem BioAssay actives

2 with measured affinity, of 14 total; 2 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
(2R)-2-[[(2R)-2-[[2-[[2-[[2-[[(2S)-2-[[(7R,10S,13S,16S,22S,25S,28S,31R,34S,37S,45S,48S,51R)-51-acetamido-45-benzyl-10-[(2S)-butan-2-yl]-34-(4-carbamimidamidobutyl)-13-(carboxymethyl)-48-(hydroxymethyl)-22,25,37-tris[(4-hydroxyphenyl)methyl]-9,12,15,21,24,27,30,33,36,39,44,47,50-tridecaoxo-28-propan-2-yl-5,53,58-trithia-8,11,14,20,23,26,29,32,35,38,43,46,49-tridecazapentacyclo[29.25.3.13,55.016,20.040,43]hexaconta-1(56),2,55(60)-triene-7-carbonyl]amino]propanoyl]-methylamino]acetyl]-methylamino]acetyl]-methylamino]acetyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoic acid	1455805: Inhibition of recombinant human C-terminal polyHis-tagged KLK13 (1 to 262 residues) expressed in HEK293 cells using fluorogenic Boc-VPR-AMC peptide as substrate by fluorescence based assay	ki	0.8200	uM
sodium [(2R)-3-[[(2S)-1-[[(2S,5S,8S,11R,12S,15Z,18S,21R)-2,5-dibenzyl-8-[(2R)-butan-2-yl]-15-ethylidene-21-hydroxy-4,11-dimethyl-3,6,9,13,16,22-hexaoxo-10-oxa-1,4,7,14,17-pentazabicyclo[16.3.1]docosan-12-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-2-methoxy-3-oxopropyl] sulfate	732086: Inhibition of Kallikrein-13 (unknown origin) using VPR-AMC substrate incubated for 15 mins prior to substrate addition measured for 2 hrs	ic50	10.0000	uM

CTD chemical–gene interactions

18 total (human), top 18 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Tobacco Smoke Pollution	affects expression, increases expression	2
Cadmium Chloride	decreases expression, increases abundance, increases expression	2
testosterone undecanoate	increases expression	1
sodium arsenite	increases abundance, affects cotreatment, decreases expression	1
3-hydroxybenzo(a)pyrene	affects expression, increases abundance	1
3-hydroxybenz(a)anthracene	affects expression, increases abundance	1
Arsenic	affects cotreatment, decreases expression, increases abundance	1
Benzo(a)pyrene	affects methylation	1
Cadmium	decreases expression, increases abundance	1
Calcitriol	increases expression	1
Formaldehyde	increases expression	1
Lead	decreases expression	1
Nickel	increases expression	1
Polycyclic Aromatic Hydrocarbons	affects expression, increases abundance	1
Tetrachlorodibenzodioxin	increases expression	1
Tretinoin	increases expression	1
Aflatoxin B1	decreases methylation	1
Lactic Acid	decreases expression	1

ChEMBL screening assays

6 unique, capped per target: 6 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL2339091	Binding	Inhibition of Kallikrein-13 (unknown origin) using VPR-AMC substrate assessed as residual activity at 10 uM incubated for 15 mins prior to substrate addition measured for 2 hrs	Potent elastase inhibitors from cyanobacteria: structural basis and mechanisms mediating cytoprotective and anti-inflammatory effects in bronchial epithelial cells. — J Med Chem

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.